Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lorenzo Trippa, Ph.D.

Co-Author

This page shows the publications co-authored by Lorenzo Trippa and Giovanni Parmigiani.
Connection Strength

2.827
  1. Statistical tools and R software for cancer driver probabilities. Methods Mol Biol. 2014; 1101:113-34.
    View in: PubMed
    Score: 0.604
  2. Frequentist operating characteristics of Bayesian optimal designs via simulation. Stat Med. 2019 09 20; 38(21):4026-4039.
    View in: PubMed
    Score: 0.220
  3. Multi-study factor analysis. Biometrics. 2019 03; 75(1):337-346.
    View in: PubMed
    Score: 0.216
  4. Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol. 2018 09; 42(6):528-538.
    View in: PubMed
    Score: 0.206
  5. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics. 2018 04 01; 19(2):199-215.
    View in: PubMed
    Score: 0.203
  6. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3160-3168.
    View in: PubMed
    Score: 0.191
  7. Bayesian response-adaptive designs for basket trials. Biometrics. 2017 09; 73(3):905-915.
    View in: PubMed
    Score: 0.188
  8. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics. 2016 06; 72(2):414-21.
    View in: PubMed
    Score: 0.172
  9. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13.
    View in: PubMed
    Score: 0.162
  10. Cross-study validation for the assessment of prediction algorithms. Bioinformatics. 2014 Jun 15; 30(12):i105-12.
    View in: PubMed
    Score: 0.156
  11. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1.
    View in: PubMed
    Score: 0.142
  12. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63.
    View in: PubMed
    Score: 0.135
  13. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848.
    View in: PubMed
    Score: 0.058
  14. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043.
    View in: PubMed
    Score: 0.052
  15. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
    View in: PubMed
    Score: 0.048
  16. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5).
    View in: PubMed
    Score: 0.038
  17. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.